Should FISH Test be Performed to all Patients With Breast Cancer?
Authors:
- Hasan MutluHMHasan Mutlu
- Halit KaracaHKHalit Karaca
- Zeki AkcaZAZeki Akca
- Yasemin Altuner TorunYTYasemin Altuner Torun
- Abdulsamet ErdenAEAbdulsamet Erden
- Tuncay AslanTATuncay Aslan
- Abdullah BuyukcelikABAbdullah Buyukcelik
Open Access
- 1 January 2013
- journal article
- Published by ScopeMed in Medicine Science | International Medical Journal
- Vol. 2 (2) , 539-47
Abstract
CerbB2 receptor determination is very important for the prognosis and treatment of breast cancer. The most used two methods for CerbB2 receptor determination are immunohistochemistry and FISH methods. FISH method is recommended for immunohistochemically CerbB2 (++) patient group. Therefore, even though the immunohistochemically CerbB2 (++) patients are in the same group, FISH test divides the results into two separate groups. Our study compared these two groups in terms of relaps duration. Total of 85 patients from The Kayseri Research and Training Hospital in Kayseri, Kayseri Erciyes University Hospital and Mersin State Hospital were included in this study. The relaps duration of the patients were determined and then compared statistically. When the mean disease free survival was compared for FISH(+) and FISH(−) groups, the mean DFS was 46±5 and 73±8 months. However, the median DFS was 38±9 months for the FISH positive group. No median PFS was reached for FISH (−) group. Immunohistochemically CerbB2 (++) breast cancer patients are considered as in the same group, however actually they have different prognostic features. Similarly, when the immunohistochemical tests and FISH tests are compared for CerbB2 positivity, different results are obtained. As a consequence of that, the therapy alternatives will be changed. Therefore, we conclude that the FISH test should be performed to all patients.Keywords
This publication has 24 references indexed in Scilit:
- Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA TrialJournal of Clinical Oncology, 2009
- HER-2-positive metastatic breast cancer: trastuzumab and beyondExpert Opinion on Pharmacotherapy, 2008
- Immunohistochemical markers as predictive tools for breast cancerJournal of Clinical Pathology, 2007
- The HER4 Cytoplasmic Domain, But Not Its C Terminus, Inhibits Mammary Cell ProliferationMolecular Endocrinology, 2007
- HER-2 (c-erbB-2) test update: Present status and problemsBreast Cancer, 2006
- Histopathologic Characteristics Predicting HER-2/neu Amplification in Breast CancerThe Breast Journal, 2005
- Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical TrialsClinical Cancer Research, 2005
- Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activationExperimental Cell Research, 2005
- Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS* StudyHistopathology, 2003
- Quantitative Evaluation of HER-2/neuStatus in Breast Cancer by Fluorescence In Situ Hybridization and by Immunohistochemistry With Image AnalysisAmerican Journal of Clinical Pathology, 2001